

60th Annual Scientific Session & Expo

E384

JACC April 5, 2011

Volume 57, Issue 17



CARDIAC FUNCTION AND HEART FAILURE

PRESERVATION OF THE CARDIAC FUNCTION IN INFARCTED RAT HEARTS BY THE TRANSPLANTATION OF ADIPOSE-DERIVED STEM CELLS WITH INJECTABLE FIBRIN SCAFFOLDS

ACC Poster Contributions

Ernest N. Morial Convention Center, Hall F

Tuesday, April 05, 2011, 9:30 a.m.-10:45 a.m.

Session Title: Cardiac Transplantation/Assist Devices -- Basic and Clinical

Abstract Category: 23. Cardiac Transplantation/Assist Devices--Basic and Clinical

Session-Poster Board Number: 1159-37

Authors: *Yi Tong Ma, Xue-lian ZHANG, Department of Cardiology of the First Affiliated Hospital, Xin Jiang Medical University, Urumqi, Xinjiang, People's Republic of China*

Background: Cell-based therapy can improve cardiac function but is limited by the low cell retention and survival within ischemic tissues. Our research is devoted to studying the usefulness of the combination of fibrin glue (as scaffold) and adipose-derived stem cells (ADSCs) to treat myocardial infarction.

Methods: The rat ADSCs were isolated from subcutaneous adipose tissues. The surface phenotype of these cells was analyzed by flow cytometry. Fibrin glue was then co-injected with ADSCs into the left ventricular wall of rat infarction models. The structure and functional consequences of transplantation were determined by detailed histological analysis and echocardiography.

Results: Most cultured ADSCs expressed CD105 and CD90, and negative for CD34 and CD45. After injection, both the 24h-cell retention and 4-week graft size were significantly higher and larger in the Fibrin+ ADSCs group than those of the ADSCs group alone ($p<0.01$). The ADSCs could differentiate into cardiomyocyte-like, endothelial and vascular smooth muscle cells *in vivo*. The heart function improved significantly in the Fibrin + ADSCs group compared with that of the ADSCs group 4 weeks after transplantation ($p<0.01$). In addition, the arteriole densities within the infarcted area improved significantly in the Fibrin+ ADSCs group compared with those in the ADSCs group 4 weeks after transplantation ($p<0.01$).

Conclusions: The ADSCs with fibrin glue has the therapeutic potential to improve the function of infarcted hearts. The method of *in situ* injectable tissue engineering combining fibrin glue with ADSCs is promising clinically.